Skip to main content

Table 1 Summary statistics describing data variables of the original study

From: A population pharmacokinetic model is beneficial in quantifying hair concentrations of ritonavir-boosted atazanavir: a study of HIV-infected Zimbabwean adolescents

Variable

Response

Length of hair (cm), median (range)

1 (0.5–1.5)

Hair weight (grams), mean (Standard Deviation; Range)

2.0 (0.15; 1.76–2.28)

Samples Below limit of quantification

 Atazanavir

18 (18)

 Ritonavir

12 (12)

Drug regimen: recruitment + follow-up, n (%)

 Tenofovir/Lamivudine/Atazanavir-ritonavir

75 (82)

 Abacavir/Didanosine /Atazanavir-ritonavir

6 (7)

 Zidovidine/Lamivudine/Atazanavir-ritonavir

6 (7)

 Abacavir/Lamivudine/Atazanavir-ritonavir

3 (3)

 Tenofovir/ Emtricitabine /Atazanavir-ritonavir

2 (2)

Body mass index-for-age, n (%)

 Normal

25 (54)

 Overweight

7 (15)

 Thinness

14 (30)

Age (years), mean (Standard Deviation; Range)

15.8 (1.8; 11–18)

Gender, n (%)

 Female

27 (54)

Caregiver, n (%)

 Parent

10 (20)

 Grandparent

20 (40)

 Sibling

5 (10)

 Aunt/uncle

15 (30)

Level of education, n (%)

 Secondary school

39 (89)

 Primary school

8 (9)

 Dropped

1 (2)

WHO disease progression stage, n (%)

 Early

16 (32)

 Late

34 (68)

Adherence by visual inspection of analogue scale, mean (Standard Deviation; Range)

84.2 (18.1; 30–100)

Atazanavir concentration (ng/mg), mean (Standard Deviation; Range)

2.5 (2.0; 0.07–8.65)

Ritonavir concentration (ng/mg), mean (Standard Deviation; Range)

0.5 (0.4; 0.01–1.39)